Once neck and neck with Valneva to get the first chikungunya vaccine to market, it now looks like Merck & Co. has admitted defeat as its French rival reaches the finish line. Merck’s contender was ...
European countries' decisions to backtrack on their large orders of Valneva’s COVID-19 vaccine appeared to have sunk the company’s hopes of developing a successor shot. But the French biotech is now ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its ...
As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. France’s public health agency, the Haute ...
Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million). The company was awarded a tropical disease PRV in November 2023 following the FDA ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results